⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9400988 | 0.70 | — | — | |
| SCHEMBL4306011 | 0.60 | — | — | |
| SCHEMBL8636117 | 0.57 | — | — | |
| SCHEMBL1503459 | 0.56 | — | — | |
| SCHEMBL1200901 | 0.56 | — | — | |
| SCHEMBL377532 | 0.56 | — | — | |
| SCHEMBL21905684 | 0.53 | — | — | |
| SCHEMBL21905674 | 0.53 | — | — | |
| SCHEMBL21905689 | 0.53 | — | — | |
| SCHEMBL21873191 | 0.53 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0667562-B1 | Charge injection barrier for positive charging organic photoconductor | HEWLETT PACKARD CO (US) | 2001-03-21 | — | — | EP | claimed |
| EP-4715896-A1 | BATTERY CELL, BATTERY COMPRISING SAME, AND ELECTRIC APPARATUS | Contemporary Amperex Technology Co., Limited (CN) | 2026-03-25 | — | — | EP | disclosed |
| WO-2023196616-A1 | FRAGRANCE AND FLAVOR MATERIALS | TAKASAGO INTERNATIONAL CORPORATION (USA) (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-4121055-A1 | STAT DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021188696-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| EP-3235818-A2 | COMPOUNDS FOR THE TREATMENT OF HIV | Critical Outcome Technologies, Inc. (CA) | 2017-10-25 | — | — | EP | disclosed |
| EP-2552915-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | CRITICAL OUTCOME TECH INC (CA) | 2017-07-19 | — | — | EP | disclosed |
| US-9624220-B2 | Compounds and method for treatment of HIV | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2017-04-18 | — | — | US | disclosed |
| US-20160333010-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF HIV | CRITICAL OUTCOME TECH INC (CA) | 2016-11-17 | — | — | US | disclosed |
| US-9422282-B2 | Compounds and method for treatment of HIV | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2016-08-23 | — | — | US | disclosed |
| US-20020019534-A1 | Gem substituted hydroxamic acids | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| EP-1138680-A1 | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors | Pfizer Products Inc. (US) | 2001-10-04 | — | — | EP | disclosed |
| US-6214870-B1 | ANTIARTHRITIC AGENTS; ANTICANCER AGENTS | PFIZER INC | 2001-04-10 | — | — | US | disclosed |
| EP-0667562-B1 | Charge injection barrier for positive charging organic photoconductor | HEWLETT PACKARD CO (US) | 2001-03-21 | — | — | EP | disclosed |
| EP-1041072-A1 | Dioxocyclopentyl hydroxamic acids | Pfizer Products Inc. (US) | 2000-10-04 | — | — | EP | disclosed |
| US-6087392-A | A METALLOPROTEINASE INHIBITORS FOR INHIBITING MAMMALIAN REPROLYSIN | PFIZER INC. (US) | 2000-07-11 | — | — | US | disclosed |
| EP-0954558-A1 | FUEL COMPOSITIONS EXHIBITING IMPROVED FUEL STABILITY | ORR, William C. (US) | 1999-11-10 | — | — | EP | disclosed |
| WO-1998026028-A1 | FUEL COMPOSITIONS EXHIBITING IMPROVED FUEL STABILITY | ORR WILLIAM C (US) | 1998-06-18 | — | — | WO | disclosed |
| EP-0780386-A1 | Matrix metalloprotease inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 1997-06-25 | — | — | EP | disclosed |
| EP-0667562-A2 | Charge injection barrier for positive charging organic photoconductor | Hewlett-Packard Company (US) | 1995-08-16 | — | — | EP | disclosed |